NextPlat (NASDAQ:NXPL – Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($0.42) earnings per share for the quarter, Zacks reports. NextPlat had a negative net margin of 21.56% and a negative return on equity of 53.22%. The firm had revenue of $9.86 million during the quarter.
Here are the key takeaways from NextPlat’s conference call:
- NextPlat said its turnaround is largely complete, with Q1 showing record-level gross margins, lower operating expenses, and a clear path to improving profitability in the second half of 2026.
- The healthcare segment posted a major improvement, with gross margin rising to 39% from about 20% a year ago and the segment generating positive operating income for the quarter.
- The company secured five new 340B pharmacy service agreements in the quarter, a record, and expects those customers to begin contributing to revenue in the third quarter after onboarding.
- Management highlighted new growth initiatives, including a nationwide fulfillment partnership and a planned e-commerce healthcare site that will sell prescription drugs, GLP-1 products, and OTC items, expected to launch before the end of Q2.
- Quarterly revenue declined year over year to about $10 million, though the company said the mix is shifting toward higher-margin contract and fulfillment revenue, while e-commerce remained steady at about $3.2 million.
NextPlat Price Performance
NXPL stock traded up $0.42 during mid-day trading on Friday, reaching $6.68. 1,288 shares of the company’s stock were exchanged, compared to its average volume of 94,457. The company has a debt-to-equity ratio of 0.05, a current ratio of 2.65 and a quick ratio of 2.27. The company has a market cap of $18.10 million, a price-to-earnings ratio of -1.52 and a beta of 1.91. The stock’s 50 day moving average is $5.42 and its 200 day moving average is $6.07. NextPlat has a 12-month low of $3.38 and a 12-month high of $11.10.
Institutional Inflows and Outflows
Analysts Set New Price Targets
Separately, Weiss Ratings raised NextPlat from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.
Get Our Latest Analysis on NextPlat
About NextPlat
NextPlat Corp operates as a healthcare and e-commerce company in Europe, North America, South America, the Asia and Pacific, and Africa. The company operates full-service retail specialty services pharmacies that provides prescription pharmaceuticals prescription pharmaceuticals, third-party administration, risk and data management services, compounded medications, tele-pharmacy services, anti-retroviral medications, medication therapy management, contracted pharmacy services, and health practice risk management to healthcare organizations and providers, as well as supplies prescription medications to long-term care facilities.
Read More
- Five stocks we like better than NextPlat
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
- TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
- The Power Grid Is Dying—Is It Time to Buy Its Replacement?
Receive News & Ratings for NextPlat Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NextPlat and related companies with MarketBeat.com's FREE daily email newsletter.
